Health Plan News logo

Nothing to see here

You seemed to have found a mislinked file, page, or search query with zero results. If you feel that you've reached this page in error, double check the URL and or search string and try again.

Alternatively, a more personalized method of tracking down and searching for content can be found below.




  • July 15th 2014
    Tags: Healthcare Plan News Comments Off

    Time Ticking for Man in Need of Non-Embryonic Stem Cell Treatment

    Marc Serchia, 56, is waiting on a miracle, and if the doctors are correct he doesn't have much more time. At the age of 39, Marc suffered a massive heart attack, faced a 5-hour surgery to repair blocked arteries, and died on the surgical table six separate times. Unbelievably, he ...
    July 15th 2014
    Tags: Hospitals Comments Off

    2014 and 2015 Best Hospitals, Ranked by US News & World Report

    US News & World Report is out with their rankings of the best hospitals according to their own survey. For the first time, the Mayo Clinic in Rochester, Minnesota, claimed the No. 1 spot, followed by Massachusetts General Hospital and Johns Hopkins Hospital. Memorial Sloan Kettering Cancer Center is ...
    May 12th 2014
    Tags: Healthcare Plan News Comments Off

    Middle East Respiratory Syndrome Case Confirmed in Orlando Florida

    The CDC (Centers for Disease Control) is confirming that a man is being treated for Middle East Respiratory Syndrome at Dr. P. Phillips Hospital in Orlando, Florida. This is the second case that has been confirmed in the United States, another case has been confirmed in Indiana. CDC officials told Click ...
    May 11th 2014
    Tags: Healthcare Plan News Comments Off

    Amgen And AstraZeneca Announce Positive Results From Phase 3 Study Of Brodalumab (AMG 827) In Patients With Moderate-to-Severe Plaque Psoriasis

    Amgen (NASDAQ: AMGN) and AstraZeneca recently announced that the Phase 3 AMAGINE-1TM study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and secondary endpoints for both evaluated doses. Brodalumab is the only investigational treatment in development that binds to the interleukin-17 (IL-17) receptor and inhibits inflammatory signaling ...
    May 11th 2014
    Tags: Healthcare Plan News Comments Off

    Eisai Adds 200 Sales Specialists to Field Force for BELVIQ

    Eisai Inc. will add more than 200 new contract sales representatives to its Metabolic Business Unit, bringing the total sales force for BELVIQ® to approximately 600, triple the size from when the FDA-approved prescription therapy for chronic weight management became available in June 2013. This expansion, which becomes effective on ...

    Search

    The archives run deep. Feel free to search older content using topic keywords.